Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry

Rhea-AI Summary

Ping An Biomedical (NASDAQ: PASW) signed a non-binding Investment Memorandum with Future Biotechnology Group on Jan 9, 2026 outlining an initial cash investment of US$30 million and subsequent acquisitions with aggregate consideration of US$60 million to be paid in cash and share issuances.

The Consideration Shares will be held in escrow and released subject to three annual audited revenue performance targets: RMB 750 million (2026), RMB 1.3 billion (2027), and RMB 2.3 billion (2028). Shortfalls reduce share releases; excess >50% can offset prior shortfalls. The deal targets integration of R&D, clinical translation, AI manufacturing, and commercialization to support Ping An Bio's technology-driven healthcare strategy.

Positive

• Initial US$30M cash investment committed
• Performance-based structure aligns incentives over 3 years
• RMB 2.3B final-year revenue target supports scale expectations
• Escrowed shares reduce immediate dilution until targets met

Negative

• Contingent consideration up to US$60M may dilute shareholders
• Revenue targets create execution risk across 2026–2028
• Non-binding memorandum lacks binding acquisition guarantees

News Market Reaction

-67.65% 109.8x vol

113 alerts

-67.65% News Effect

+35.6% Peak Tracked

-77.2% Trough Tracked

-$27M Valuation Impact

$13M Market Cap

109.8x Rel. Volume

On the day this news was published, PASW declined 67.65%, reflecting a significant negative market reaction. Argus tracked a peak move of +35.6% during that session. Argus tracked a trough of -77.2% from its starting point during tracking. Our momentum scanner triggered 113 alerts that day, indicating very high trading interest and price volatility. This price movement removed approximately $27M from the company's valuation, bringing the market cap to $13M at that time. Trading volume was exceptionally heavy at 109.8x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Initial investment: US$30 million Subsequent acquisitions: US$60 million 2026 revenue target: RMB 750 million +4 more

7 metrics

Initial investment US$30 million Cash investment under non-binding Investment Memorandum

Subsequent acquisitions US$60 million Aggregate consideration in cash and share issuances

2026 revenue target RMB 750 million Audited revenue minimum for Jan 1–Dec 31, 2026

2027 revenue target RMB 1.3 billion Audited revenue minimum for Jan 1–Dec 31, 2027

2028 revenue target RMB 2.3 billion Audited revenue minimum for Jan 1–Dec 31, 2028

Consideration share tranches One-fifth per period Shares released each assessment period subject to performance

Evaluation period length 3 years From January 2026 to December 2028

Market Reality Check

Price: $0.2680 Vol: Volume 997,802 is 4.93x t...

high vol

$0.2680 Last Close

Volume Volume 997,802 is 4.93x the 20-day average of 202,414, indicating elevated trading interest. high

Technical Price at 0.6183 is trading below the 200-day MA of 0.66 and remains 49.32% under the 52-week high.

Historical Context

1 past event · Latest: Nov 28 (Negative)

1 events

Date	Event	Sentiment	Move	Catalyst
Nov 28	Listing compliance update	Negative	-3.6%	Nasdaq minimum bid price deficiency letter and compliance timeline disclosure.

Recent Company History

In the past six months, PASW’s disclosed news flow has focused on listing compliance. On Nov 28, 2025, the company reported a Nasdaq minimum bid price deficiency covering Oct 10–Nov 20, 2025, with a 180-day cure period ending May 25, 2026, and potential for an additional 180 days. That update saw a -3.59% price move. Today’s strategic investment announcement contrasts with that prior compliance-focused disclosure by emphasizing business expansion and revenue-linked performance targets.

Market Pulse Summary

The stock dropped -67.7% in the session following this news. A negative reaction despite this invest...

Analysis

The stock dropped -67.7% in the session following this news. A negative reaction despite this investment would contrast the announced US$30 million initial commitment and up to US$60 million in follow-on consideration linked to revenue targets as high as RMB 2.3 billion. Investors may still be focused on prior listing-compliance risks and the stock’s position below the 0.66 200-day MA and far under its 52-week high, while the multi-year performance and cancellation mechanics for consideration shares could add perceived execution risk.

Key Terms

genetic testing, artificial intelligence, precision medicine

3 terms

genetic testing medical

"Its core businesses include biopharmaceutical research and development, genetic testing,"

Genetic testing analyzes a person’s DNA to find changes that affect health, disease risk, or how someone may respond to medicines. For investors, these tests can create or shrink markets for diagnostics, drugs and personalized care, influence regulatory decisions and reimbursement, and alter company valuations—much like a weather forecast changes choices and risks for farmers preparing a crop.

artificial intelligence technical

"advancing its “AI Intelligent Manufacturing” strategy, deeply integrating artificial intelligence"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

precision medicine medical

"drug discovery, manufacturing processes, and precision medicine, continuously enhancing"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. Not financial advice.

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”).

The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the “Consideration Shares”). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation period of 3 years from January 2026 to December 2028.

Performance Targets

January 1, 2026 – December 31, 2026:
The target company shall achieve audited revenue of no less than RMB 750 million.

January 1, 2027 – December 31, 2027:
The target company shall achieve audited revenue of no less than RMB 1.3 billion.

January 1, 2028 – December 31, 2028:
The target company shall achieve audited revenue of no less than RMB 2.3 billion.

The consideration shares shall be subject to adjustment in accordance with the agreed terms. If the seller fails to meet the agreed performance targets in any assessment period, the number of shares to be released for that period (representing one-fifth of the total consideration shares) shall be deducted based on the agreed formula. The deducted consideration shares will be cancelled by the company. Conversely, if the seller exceeds the performance target by more than 50% in any assessment period, the excess revenue may be used to offset shortfalls from any previous assessment periods.

Future Biotechnology Group is an innovative technology enterprise focused on the biopharmaceutical sector. Its core businesses include biopharmaceutical research and development, genetic testing, medical devices, and pharmaceutical sales. The company is also comprehensively advancing its “AI Intelligent Manufacturing” strategy, deeply integrating artificial intelligence into key areas such as drug discovery, manufacturing processes, and precision medicine, continuously enhancing R&D efficiency and industrial commercialization capabilities. In addition, the group has established long-term and stable strategic partnerships with multiple medical institutions.

Ping An Biomedical Co., Ltd stated that this strategic investment aligns with the company’s long-term development strategy of “technology empowering healthcare.” Through synergistic cooperation with Future Biotechnology Group, the company will further integrate biopharmaceutical R&D, clinical translation, and industrial resources, accelerate the large-scale application of innovative technologies, and enhance overall industry competitiveness.

Against the backdrop of the biopharmaceutical industry’s transition toward high-quality development, industrial integration with clear technological pathways, well-defined performance targets, and robust incentive mechanisms is expected to unlock long-term growth potential. Through this strategic investment, Ping An Bio has laid a solid foundation for its continued expansion in the biopharmaceutical sector.

About Ping An Biomedical Co., Ltd

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.

Safe Harbor and Informational Statement

This announcement contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words "believe," "expect," "anticipate," "future," "will," "intend," "plan," "estimate" or similar expressions, are "forward-looking statements". Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to timely and accurately respond to changes in fashion trends and consumer preferences; management of customer concentration risk; reliance on third parties for supplies of raw materials, manufacturing services and transport infrastructure; changes in government policy in China; China's overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in Ping An Biomedical Co., Ltd’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of the issuance, and Ping An Biomedical Co., Ltd does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Ping An Biomedical Co., Ltd.
Email: corpsec@pingan365.vip

Celestia Investor Relations
Email: investors@celestiair.com

FAQ

What amount did Ping An Biomedical commit to invest in Future Biotechnology Group (PASW)?

Ping An Biomedical committed an initial US$30 million in cash, with up to US$60 million additional consideration in cash and shares.

What are the 2026–2028 revenue performance targets tied to PASW consideration shares?

The targets are audited revenue of RMB 750M (2026), RMB 1.3B (2027), and RMB 2.3B (2028).

How are the Consideration Shares released under the PASW memorandum?

Shares are escrowed and released annually over three years; missed targets reduce that period's share release per the agreed formula.

Could Future Biotechnology Group's excess revenue affect PASW share releases?

Yes — if revenue exceeds a period's target by >50%, the excess may offset prior period shortfalls.

Is the Ping An Biomedical investment in Future Biotechnology Group a binding acquisition?

No — the parties signed a non-binding Investment Memorandum outlining the proposed cash and share consideration.